We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-9.72%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$637M
AUM Growth
-$173M
Cap. Flow
-$30.7M
Cap. Flow %
-4.82%
Top 10 Hldgs %
65.73%
Holding
51
New
1
Increased
5
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
SRZN icon
Surrozen
SRZN
+$2.81M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$2.74M
3
TNGX icon
Tango Therapeutics
TNGX
+$2.4M
4
ALLK
Allakos
ALLK
+$2.31M
5
ELEV
Elevation Oncology
ELEV
+$11

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$7.21M
2
JANX icon
Janux Therapeutics
JANX
+$5.64M
3
CHFW.U
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
+$3.12M
4
ALPN
Alpine Immune Sciences Inc
ALPN
+$2.48M
5
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
+$2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.27%
2 Financials 1.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHFW.U
51
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
– –
-300,000
Closed -$3.12M
1 2
3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q3 2021 Portfolio in Review

As of Q3 2021, Samsara BioCapital held 51 positions worth $637M, down 21% from $810M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Samsara BioCapital withdrew a net $30.7M in Q3 2021, closing 3 positions and reducing 8 holdings. Its most notable exit was Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third, an estimated $3.12M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Financials.

Against the trend, Samsara BioCapital opened a new position in Surrozen worth $2.12M.

  • Samsara BioCapital's largest Q3 2021 buy was Surrozen: 20,000 shares worth $2.12M.
  • Samsara BioCapital added most to Chinook Therapeutics, Inc. Common Stock in Q3 2021, an estimated $2.74M increase.
  • Samsara BioCapital's biggest Q3 2021 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $7.21M.
  • Samsara BioCapital fully exited Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third in Q3 2021, selling an estimated $3.12M.
  • Samsara BioCapital's ten largest holdings make up 66% of its $637M portfolio in Q3 2021.
  • Samsara BioCapital opened 1 new position and closed 3 in Q3 2021.
  • Samsara BioCapital's portfolio value fell 21% quarter-over-quarter to $637M.

Based on Samsara BioCapital's 13F filing for Q3 2021, filed 15 Nov 2021.